Editorial: Immunotherapy as an Evolving Approach for the Treatment of Breast Cancer

Código QR

Editorial: Immunotherapy as an Evolving Approach for the Treatment of Breast Cancer

Guardado en:

Detalles Bibliográficos
Autores principales:	Mai F. Tolba, Cesar A. Santa-Maria, Adriana Albini, Emile R. Chimusa, Basel K. Al-Ramadi, Sara M. Tolaney
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	immunotherapy breast cancer immune checkpoint inhibitors combination therapy biomarker Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/c941230005bc480e9524d9065aec0e9e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches
por: Ayoub NM, et al.
Publicado: (2019)

Progress in the Application of Immune Checkpoint Inhibitor-Based Immunotherapy for Targeting Different Types of Colorectal Cancer
por: Rui He, et al.
Publicado: (2021)

Combined treatment of non‐small cell lung cancer using radiotherapy and immunotherapy: challenges and updates
por: Shijie Shang, et al.
Publicado: (2021)

A review on the evolution of immunotherapy in bladder carcinoma
por: Milena Gulinac, et al.
Publicado: (2020)

Targeting Tumor-Associated Macrophages in Cancer Immunotherapy
por: Amy J. Petty, et al.
Publicado: (2021)

Neoadjuvant Therapy Using Checkpoint Inhibitors before Radical Cystectomy for Muscle Invasive Bladder Cancer: A Systematic Review
por: Hadi SHSM, et al.
Publicado: (2021)

Overweight as a Favorable Clinical Biomarker for Checkpoint Inhibitor Therapy Response in Recurrent Gynecologic Cancer Patients
por: Thomas Bartl, et al.
Publicado: (2021)

Cancer Vaccines and Immunotherapy for Tumor Prevention and Treatment
por: Jagmohan Singh, et al.
Publicado: (2021)

Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma
por: Petros Fessas, et al.
Publicado: (2021)

Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance
por: Xupeng Bai, et al.
Publicado: (2021)

Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China
por: Anwen Xiong, et al.
Publicado: (2021)

Clinical Trial Progress and Application of Immune Checkpoint Inhibitors  in the Treatment of Small Cell Lung Cancer
por: Huiqiu ZHANG, et al.
Publicado: (2021)

Should we be Afraid of Immune Check Point Inhibitors in Cancer Patients with Pre-Existing Rheumatic Diseases? Immunotherapy in Pre-Existing Rheumatic Diseases
por: Kalliopi Klavdianou, et al.
Publicado: (2021)

Prognostic and Predictive Factors in Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Review of the Current Evidence
por: Sara Elena Rebuzzi, et al.
Publicado: (2021)

Pan-Cancer Analysis Reveals Alternative Splicing Characteristics Associated With Immune-Related Adverse Events Elicited by Checkpoint Immunotherapy
por: Xiujing He, et al.
Publicado: (2021)

Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer
por: Chinese Society of Clinical Oncology, Expert Committee on Tumor Vascular-targeted Therapy, et al.
Publicado: (2021)

Immune modulation underpins the anti‐cancer activity of HDAC inhibitors
por: Wiktoria Blaszczak, et al.
Publicado: (2021)

Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors
por: Qi J, et al.
Publicado: (2021)

Immunotherapy in Medulloblastoma: Current State of Research, Challenges, and Future Perspectives
por: Marije J. Voskamp, et al.
Publicado: (2021)

Nanosonosensitizer-Augmented Sonodynamic Therapy Combined with Checkpoint Blockade for Cancer Immunotherapy
por: Lin X, et al.
Publicado: (2021)

The Half-Life-Extended IL21 can Be Combined With Multiple Checkpoint Inhibitors for Tumor Immunotherapy
por: Shaoxian Wu, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers
por: Brian W. Labadie, et al.
Publicado: (2021)

Clinical case of long-term use of durvalumab in the treatment of advanced small-cell lung cancer
por: Galina B. Statsenko, et al.
Publicado: (2020)

Factors associated with immunotherapy respond and survival in advanced non-small cell lung cancer patients
por: Yahua Wu, et al.
Publicado: (2022)

Multi-Omics Analysis of Novel Signature for Immunotherapy Response and Tumor Microenvironment Regulation Patterns in Urothelial Cancer
por: Guangdi Chu, et al.
Publicado: (2021)

Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial)
por: Nieves Martinez Chanza, et al.
Publicado: (2021)

Immunotherapy in Breast Cancer: When, How, and What Challenges?
por: Beatriz Henriques, et al.
Publicado: (2021)

Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma
por: Rui Xing, et al.
Publicado: (2021)

Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy
por: Masmudur M. Rahman, et al.
Publicado: (2021)

Personalized immunotherapy in cancer precision medicine
por: Kazuma Kiyotani, et al.
Publicado: (2021)

Neoantigen Dendritic Cell Vaccination Combined with Anti-CD38 and CpG Elicits Anti-Tumor Immunity against the Immune Checkpoint Therapy-Resistant Murine Lung Cancer Cell Line LLC1
por: Changbo Sun, et al.
Publicado: (2021)

New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab
por: Seetharamu N, et al.
Publicado: (2017)

Persistent Response to a Combination Treatment Featuring a Targeted Agent and an Immune Checkpoint Inhibitor in a Patient With Collecting Duct Renal Carcinoma: A Case Report and Literature Review
por: Weimin Zhou, et al.
Publicado: (2021)

VISTA Is a Diagnostic Biomarker and Immunotherapy Target of Aggressive Feline Mammary Carcinoma Subtypes
por: Andreia Gameiro, et al.
Publicado: (2021)

An Agent-Based Model of Combination Oncolytic Viral Therapy and Anti-PD-1 Immunotherapy Reveals the Importance of Spatial Location When Treating Glioblastoma
por: Kathleen M. Storey, et al.
Publicado: (2021)

Deciphering the nonsense-mediated mRNA decay pathway to identify cancer cell vulnerabilities for effective cancer therapy
por: Roberta Bongiorno, et al.
Publicado: (2021)

Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis
por: Nuttapong Ngamphaiboon, et al.
Publicado: (2021)

Current Strategies for Tumor Photodynamic Therapy Combined With Immunotherapy
por: Jianfeng Hua, et al.
Publicado: (2021)

Advances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer
por: Chuan HUANG, et al.
Publicado: (2021)

Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma
por: Kimberly M. Burcher, et al.
Publicado: (2021)